Home > Companies > Alnylam Pharmaceuticals

Alnylam Pharmaceuticals

We are developing an innovative, entirely new class of medicines called “RNAi therapeutics” to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNA interference (RNAi), and a bold vision that this discovery could be used to silence disease-causing genes upstream of today’s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn’t have to wait for hope.

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

Drug Delivery and Nanomedicine

Drug Discovery And Communal Trial

Medicinal Chemistry and Drug Design

World Drug Safety Congress Europe

7th Edition of Global Conference on Pharmaceutics and Novel Drug Delivery Systems

Pharma Manufacturing And Automation

Related News

PANTHERX® RARE PHARMACY SELECTED BY ALNYLAM PHARMACEUTICALS TO DISTRIBUTE GIVLAARI™ (GIVOSIRAN)

PR Newswire | December 12, 2019

PANTHERx® Rare Pharmacy announces that it has been selected by Alnylam Pharmaceuticals as a very limited distribution partner for the novel drug GIVLAARI™ (givosiran). GIVLAARI is the first and only FDA-approved medicine indicated for the treatment of adults with Acute Hepatic Porphyria (AHP). GIVLAARI becomes the second RNAi therapeutic from Alnylam approved by the FDA in the last 16 months and the first-ever approved GalNAc-Conjugate RNA therapeutic, a landmark in the advancement of ...

BUSINESS INSIGHTS

ALNYLAM ANNOUNCES 3-MONTH EXTENSION OF REVIEW PERIOD FOR NEW DRUG APPLICATION FOR VUTRISIRAN

Alnylam Pharmaceuticals, Inc. | April 05, 2022

Alnylam Pharmaceuticals, Inc. the leading RNAi therapeutics company, announced that the U.S. Food and Drug Administration has extended the review timeline of the New Drug Application for vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated amyloidosis, to allow for the review of newly added information related to the new secondary packaging and labeling facility. Alnylam recently learned that the original third-party secondary packaging and l...

GROUND-BREAKING COLLABORATION TO OFFER NEW HEART DISEASE DRUG TO NHS PATIENTS

Pharmacy Business | January 14, 2020

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...

POLL: UTAH VOTERS BACK CAP ON CO-PAYS FOR INSULIN PRESCRIPTIONS

Public News Service | January 14, 2020

The skyrocketing cost of prescription drugs has become a bipartisan issue among voters, and Utahns overwhelmingly back a plan to help diabetics overcome the cost of life-saving insulin. A new poll from UtahPolicy.com Y-2 Analytics finds 4 out of 5 registered voters would support legislation to cap out-of-pocket costs for insulin. The idea mirrors a bill passed in Colorado in 2019 to limit a patient's out-of-pocket costs for insulin, a hormone critical to diabetics for controlling their blood...